TG Therapeutics Reports Strong 2025 BRIUMVI Revenue, Issues Bullish 2026 Guidance, and Outlines Key Pipeline Milestones
TGTX sits 18% above its 52-week low of $25.28 on elevated volume (1.8× avg).
Summary
TG Therapeutics announced strong preliminary 2025 revenue and provided bullish 2026 guidance for its key drug BRIUMVI, alongside outlining significant development milestones for its pipeline.
Key Events · Earnings and Guidance · TGTX
-
Strong 2025 Revenue Performance
Preliminary total global revenue for full year 2025 reached approximately $616 million, with U.S. BRIUMVI net product revenue at $594 million.
-
Bullish 2026 Revenue Guidance
The company projects total global revenue of $875-900 million for full year 2026, including $825-850 million from U.S. BRIUMVI sales, indicating substantial growth.
-
Key Development Milestones
Multiple pipeline catalysts are anticipated for 2026, including pivotal data for IV BRIUMVI dosing, preliminary Phase 1 azer-cel data in Progressive MS, and pivotal data for subcutaneous BRIUMVI.
-
Pipeline Expansion
Plans to initiate registration-directed and exploratory studies for BRIUMVI and azer-cel in new autoimmune indications beyond MS.
Analysis · TGTX · Life Sciences
TG Therapeutics has reported strong preliminary net product revenue for BRIUMVI in Q4 and full year 2025, exceeding $600 million globally. The company also provided robust 2026 revenue guidance, targeting $875-900 million in total global revenue, driven primarily by BRIUMVI U.S. sales. This significant growth trajectory, coupled with a detailed roadmap of anticipated development milestones for BRIUMVI (including subcutaneous formulation and new indications) and azer-cel, signals strong commercial momentum and a promising pipeline. Investors should view this as a positive indicator of the company's ability to execute on its commercial strategy and advance its therapeutic candidates.
At the time of this filing, TGTX was trading at $29.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $25.28 to $46.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.